Investors

DevaCell is developing a product pipeline of next-generation therapies, vaccines and gene therapies across a wide range of disease indications. Our novel ONCoat system viral vector engineering platform enables the development of product candidates that can be systemically delivered, as well as administered repeatedly, enabling fast-track development across a range of indications. DevaCell intends to progress these therapies rapidly through discovery, pre-clinical and clinical development as internal development programs, along with synergistic strategic partners when appropriate.

Leave a Reply

Your email address will not be published. Required fields are marked *